KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Long-Term Debt Repayments (2016 - 2024)

Ionis Pharmaceuticals has reported Long-Term Debt Repayments over the past 13 years, most recently at $44.5 million for Q4 2024.

  • Quarterly results put Long-Term Debt Repayments at $44.5 million for Q4 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $114.8 million (up 63.31% YoY), and the annual figure for FY2024 was $44.5 million, down 90.88%.
  • Long-Term Debt Repayments for Q4 2024 was $44.5 million at Ionis Pharmaceuticals, down from $70.3 million in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for IONS hit a ceiling of $70.3 million in Q3 2023 and a floor of -$37000.0 in Q2 2021.
  • Median Long-Term Debt Repayments over the past 3 years was $48.7 million (2021), compared with a mean of $41.9 million.